Giant Panda RLN3 ELISA Detection Using Monoclonal Antibodies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is currently a lack of methods for detecting the level of giant panda relaxin-3 (RLN3) and monitoring changes in RLN3 levels, which is significant for understanding and monitoring the reproduction of giant pandas.
Innovation Solution
Development of an ELISA method using a specific anti-giant panda RLN3 monoclonal antibody as a coating antibody and an anti-RLN3 polyclonal antibody as a labeling antibody, in conjunction with a giant panda RLN3 recombinant protein, to detect RLN3 in giant panda urine.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a detection method for giant panda RLN3 is established, then the ability to monitor RLN3 changes and assess reproductive health is improved, but the complexity of the detection system increases due to the need for specific monoclonal and polyclonal antibodies
Solution Approach 1:
The patent applies preliminary action by pre-preparing and characterizing specific monoclonal antibodies (including heavy and light chain sequences) and polyclonal antibodies against giant panda RLN3 before the actual detection process. These antibodies are developed, purified, and validated in advance to ensure reliable detection when needed, eliminating the need to develop new antibodies for each detection task.
Solution Approach 2:
The patent uses recombinant RLN3 protein as a standardized reference copy for calibration and validation of the detection system. This reference protein serves as a consistent benchmark that can be replicated and used across multiple detection runs, ensuring reliability without requiring the complex biological samples themselves.
2Measurement precision
If specific monoclonal and polyclonal antibodies are developed for RLN3 detection, then measurement precision is improved, but the time and resources required for antibody development and production increase
Solution Approach 1:
The patent performs preliminary action by completing the full antibody development process in advance, including immunization protocols, hybridoma cell line establishment, antibody purification, and characterization. The monoclonal antibodies with defined heavy and light chain sequences and polyclonal antibodies are prepared beforehand, so only the actual ELISA detection remains when measurement is needed.
Solution Approach 2:
The patent optimizes detection precision by carefully controlling parameters including antibody concentrations, incubation times and temperatures, washing conditions, and substrate reaction parameters. These parameter optimizations are performed during the method development phase to achieve high precision measurements.
3Reliability
If an ELISA method with multiple antibodies is used for RLN3 detection, then detection reliability is improved, but the operational complexity and steps required increase
Solution Approach 1:
The patent segments the detection system into distinct functional components: monoclonal antibodies for specific antigen binding, polyclonal antibodies for detection, recombinant RLN3 as reference standard, and standardized buffer solutions. Each component has a defined role and can be prepared and stored separately, making the overall process more manageable despite the multiple steps involved.
Solution Approach 2:
The patent uses recombinant RLN3 protein as an intermediary standard that mediates between the antibody reagents and the actual sample measurements. This reference protein serves as a bridge for calibration and validation, ensuring reliable detection while providing a simple, stable reference point that simplifies the operational workflow.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method allows for the timely monitoring of RLN3 changes in giant pandas, providing a means to reflect RLN levels and potentially guide reproductive health assessments.
Implementation Method 1
conducting ELISA with an anti-giant panda RLN3 monoclonal antibody produced by a hybridoma cell line RLN-3 as a coating antibody and an anti-RLN3 polyclonal antibody as a labeling antibody
Implementation Method 2
enzyme-linked immunosorbent assay (ELISA) method
Data Source
AI summary
An enzyme-linked immunosorbent assay (ELISA) method and a monoclonal antibody for giant panda relaxin-3 (RLN3) are provided. The method includes: conducting ELISA with an anti-giant panda RLN3 monoclonal antibody as a coating antibody and an anti-RLN3 polyclonal antibody as a labeling antibody, where the anti-giant panda RLN3 monoclonal antibody is secreted by a hybridoma cell line RLN-3; and the hybridoma cell line RLN-3 was deposited in the China Center for Type Culture Collection (CCTCC) of Wuhan University, Wuhan, China on Jan. 7, 2021, with an accession number of CCTCC NO: C202129. In addition, an ELISA method for detecting RLN3 in giant panda urine is developed, in which a prepared anti-giant panda RLN3 monoclonal antibody is used as a coating antibody and an anti-giant panda RLN3 polyclonal antibody is used as a labeling antibody. The method can monitor a change in giant panda RLN3 timely by determining giant panda RLN3.